Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)’s share price hit a new 52-week low on Thursday . The company traded as low as $1.40 and last traded at $0.00, with a volume of shares.

Separately, Zacks Investment Research raised Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th.

The company has a quick ratio of 1.55, a current ratio of 1.88 and a debt-to-equity ratio of 1.68.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last issued its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.29. The firm had revenue of $6.86 million for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 242.66% and a negative net margin of 57.07%.

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its stake in Imprimis Pharmaceuticals by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 35,606 shares of the specialty pharmaceutical company’s stock valued at $114,000 after acquiring an additional 13,455 shares in the last quarter. KCG Holdings Inc. purchased a new position in Imprimis Pharmaceuticals during the 1st quarter valued at about $130,000. Finally, Vanguard Group Inc. grew its stake in Imprimis Pharmaceuticals by 78.2% during the 2nd quarter. Vanguard Group Inc. now owns 451,226 shares of the specialty pharmaceutical company’s stock valued at $1,444,000 after acquiring an additional 198,068 shares in the last quarter. 17.96% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/04/imprimis-pharmaceuticals-inc-immy-reaches-new-52-week-low-at-1-40.html.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.